News und Analysen
![Why 2017 Was a Year to Remember for Johnson & Johnson](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Why 2017 Was a Year to Remember for Johnson & Johnson
With less than two weeks remaining in 2017, Johnson & Johnson (NYSE: JNJ) is on track to have its second-best year of the century so far for stock performance. The healthcare giant's share....
![Why 2017 Was a Year to Remember for Johnson & Johnson](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Why 2017 Was a Year to Remember for Johnson & Johnson
With less than two weeks remaining in 2017, Johnson & Johnson (NYSE: JNJ) is on track to have its second-best year of the century so far for stock performance. The healthcare giant's share....
![Why Mattel, Marinus Pharmaceuticals, and Northern Dynasty Minerals Slumped Today](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Why Mattel, Marinus Pharmaceuticals, and Northern Dynasty Minerals Slumped Today
Monday was another record-setting day for major benchmarks, which had solid gains of between 0.5% and 1%. Market participants were optimistic that they'll get the corporate tax cuts that they've....
![Why Riot Blockchain, Inc Stock Is Soaring on Monday](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Why Riot Blockchain, Inc Stock Is Soaring on Monday
Shares of Riot Blockchain (NASDAQ: RIOT) are soaring, rising about 22% as of 12:30 p.m. EST. The company's soaring share price follows the launch of CME's bitcoin futures and a short-lived surge....
![3 Growth Stocks to Own in 2018](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
3 Growth Stocks to Own in 2018
With U.S. stocks at all-times highs, it can be a serious challenge to find growth vehicles that are still worth buying at these levels. To do so, I think investors may want to try to mine the....
![Is Cara Therapeutics, Inc. a Buy?](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Is Cara Therapeutics, Inc. a Buy?
Small-cap biotech Cara Therapeutics (NASDAQ: CARA) is working to commercialize a drug to combat pain -- but the stock has managed to inflict a different sort of suffering on its investors in....
![The 5 Best-Selling Drugs of 2017](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
The 5 Best-Selling Drugs of 2017
We spent $328.6 billion on prescription drugs in 2016 -- and that's just the United States. The amount will no doubt be higher when the books are closed on 2017.Payers and patients across the....
![The 3 Best Biotech Stocks of 2017](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
The 3 Best Biotech Stocks of 2017
Biotech stocks rocked in 2017. At least a lot of them did. The SPDR S&P Biotech ETF has chalked up a gain of 40% with only a couple of weeks left in the year -- twice the return of the S&P....
![Here's Why GlycoMimetics Could Become a Takeover Target](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Here's Why GlycoMimetics Could Become a Takeover Target
Updated results from a trial evaluating GMI-1271 in relapsed or refractory acute myeloid leukemia (AML) sent GlycoMimetics (NASDAQ: GLYC) shares soaring earlier this week, but more good news next....
![3 Top Dividend Aristocrats to Buy for 2018](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
3 Top Dividend Aristocrats to Buy for 2018
It's quite an honor for a stock to land on the list of Dividend Aristocrats. Income investors like the stability of large-cap stocks that have not only paid out but also increased their dividends....
![Better Buy: Johnson & Johnson vs. Merck](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Better Buy: Johnson & Johnson vs. Merck
This big pharma claims one of the hottest cancer drugs around. But it also faces challenges for some of its biggest-selling drugs. Which big pharma is it?Actually, it's two: Johnson & Johnson....
![Better Buy: Johnson & Johnson vs. Merck](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Better Buy: Johnson & Johnson vs. Merck
This big pharma claims one of the hottest cancer drugs around. But it also faces challenges for some of its biggest-selling drugs. Which big pharma is it?Actually, it's two: Johnson & Johnson....
![Even in This Rich Market, Gilead Sciences, Inc. Is Offering Investors Value](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Even in This Rich Market, Gilead Sciences, Inc. Is Offering Investors Value
Major stock market indexes keep hitting record highs, but shares of Gilead Sciences, Inc. (NASDAQ: GILD) have been moving in the opposite direction. Although profits have fallen in recent....
![Even in This Rich Market, Gilead Sciences, Inc. Is Offering Investors Value](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Even in This Rich Market, Gilead Sciences, Inc. Is Offering Investors Value
Major stock market indexes keep hitting record highs, but shares of Gilead Sciences, Inc. (NASDAQ: GILD) have been moving in the opposite direction. Although profits have fallen in recent....
![Even in This Rich Market, Gilead Sciences, Inc. Is Offering Investors Value](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Even in This Rich Market, Gilead Sciences, Inc. Is Offering Investors Value
Major stock market indexes keep hitting record highs, but shares of Gilead Sciences, Inc. (NASDAQ: GILD) have been moving in the opposite direction. Although profits have fallen in recent....
![3 Top Small-Cap Stocks to Buy in December](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
3 Top Small-Cap Stocks to Buy in December
Small-cap stocks are riskier than their blue-chip peers, but they can also deliver incredible gains. The trick is finding solid businesses that the rest of the market is overlooking, putting your....
![Alnylam Gets Some Welcome News](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Alnylam Gets Some Welcome News
The FDA has agreed to allow Alnylam (NASDAQ: ALNY) and Sanofi (NYSE: SNY) to resume trials of their hemophilia therapy, fitusiran. Previously, these companies had to halt their fitusiran studies....
![This Tiny Biotech Pins Hope on U.S. Approval](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
This Tiny Biotech Pins Hope on U.S. Approval
Amicus Therapeutics (NASDAQ: FOLD) already markets its Fabry disease drug Galafold overseas, and it hopes it will soon be able to help patients in the U.S., too. Yesterday, management reported....
![Better Buy: Illumina, Inc. vs. Thermo Fisher Scientific](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Better Buy: Illumina, Inc. vs. Thermo Fisher Scientific
It's been a really good year for Thermo Fisher Scientific (NYSE: TMO). The medical and laboratory instrument maker's stock is up nearly 36% so far in 2017, nearly double the increase for the....
![Better Buy: Illumina, Inc. vs. Thermo Fisher Scientific](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Better Buy: Illumina, Inc. vs. Thermo Fisher Scientific
It's been a really good year for Thermo Fisher Scientific (NYSE: TMO). The medical and laboratory instrument maker's stock is up nearly 36% so far in 2017, nearly double the increase for the....
![Better Buy: Illumina, Inc. vs. Thermo Fisher Scientific](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Better Buy: Illumina, Inc. vs. Thermo Fisher Scientific
It's been a really good year for Thermo Fisher Scientific (NYSE: TMO). The medical and laboratory instrument maker's stock is up nearly 36% so far in 2017, nearly double the increase for the....
![What to Expect From AbbVie Inc. in 2018](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
What to Expect From AbbVie Inc. in 2018
In the words of the legendary James Brown, I feel good.Early this year, I bought a position in AbbVie (NYSE: ABBV). The big pharma stock is on track for 2017 to be its best year ever. And I'm....
![Why Genomic Health, Inc. Skyrocketed Today](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Why Genomic Health, Inc. Skyrocketed Today
Genomic Health (NASDAQ: GHDX) is up 21% at 1:12 p.m. EST Thursday after Bloomberg reported that the cancer test company is contemplating selling itself after receiving takeover interest.While it's....
![Here's Why Marinus Pharmaceuticals Is Soaring Today](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Here's Why Marinus Pharmaceuticals Is Soaring Today
Welcome to the popular clique, kid. Shares of clinical-stage biopharma Marinus Pharmaceuticals (NASDAQ: MRNS) rose as much as 22.2% by noon EST after the company announced it will be added to the....
![BOIRON : Acquisition of trademarks and patents](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
BOIRON : Acquisition of trademarks and patents
The BOIRON Laboratories have acquired from the Swiss company ALKANTIS the trademarks and patents relating to its medical device for analgesic, anti-inflammatory and anti-oedematous purposes....